— Know what they know.
Not Investment Advice

Financial News

Sentiment 16.4 5099 articles 2607 bullish 1237 bearish Full Index →
Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight D

Rhythm Pharma Wins FDA Approval For First-Ever Rare Weight Disorder Therapy

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s...
📰

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
📰

Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?

Here is how Aura Biosciences, Inc. (AURA) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.
📰

Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks....
📰

Here's Why Integer (ITGR) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5W PR Delivers High-Impact PR Strategies for B2B Companies N

5W PR Delivers High-Impact PR Strategies for B2B Companies Navigating Competitive and Emerging Industries

NEW YORK, March 20, 2026 /PRNewswire/ -- 5W PR, one of the largest independently owned PR firms in the U.S., today announced the launch of its...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term...
How To Spot An AI Tax Scam This Filing Season

How To Spot An AI Tax Scam This Filing Season

Tax scams are growing more sophisticated this filing season, with artificial intelligence giving fraudsters new tools to impersonate government...
📰

CIMG Inc. Announces Liquidity Provider Agreement with The Ching Labs to Support DeSyn Pool TVL

HONG KONG, March 20, 2026 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: CIMG), a business group specializing in digital health and...
Google Brings Gemini To Mac In Early Test To Rival ChatGPT

Google Brings Gemini To Mac In Early Test To Rival ChatGPT

Alphabet Inc.’s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google is stepping up its AI push with a dedicated Gemini app for Apple Inc.’s (NASDAQ:AAPL)...
📰

Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings...
📰

Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This Rubrik Analyst Begins Coverage On A Bullish Note; Here

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
Investors Heavily Search Tenet Healthcare Corporation (THC):

Investors Heavily Search Tenet Healthcare Corporation (THC): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Tenet (THC). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Here is What to Know Beyond Why Bristol Myers Squibb Company

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's...
The Gold Mine That Barrick Bought Into, a Billionaire Backed

The Gold Mine That Barrick Bought Into, a Billionaire Backed, and the Market Still Hasn't Found

LVG, KGC, FNV, WPM, and EQX as the Gold Supercycle Enters Its Most Profitable Phase Issued on behalf of Lake Victoria Gold Ltd. Companies mentioned...
📰

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc....
📰

QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class Action Lawsuit — The Gross Law Firm

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V....
📰
📰
What's Going On With GSI Technology Stock Today?

What's Going On With GSI Technology Stock Today?

GSI Technology (NASDAQ:GSIT) shares are down during Friday’s premarket session as the company announced the conclusion of its strategic...
📰

BioLineRx FY 2025 Earnings Preview

FNB Selected as Penn State's Official Provider of Retail Ban

FNB Selected as Penn State's Official Provider of Retail Banking and Financial Services

UNIVERSITY PARK, Pa., March 20, 2026 /PRNewswire/ -- F.N.B. Corporation (NYSE: FNB) today announced a partnership with Penn State that establishes...
📰

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company...
BTS Comeback Becomes Netflix's Biggest Live Bet Yet

BTS Comeback Becomes Netflix's Biggest Live Bet Yet

Netflix Inc. (NASDAQ:NFLX) is expanding its growth strategy across content, live experiences, and internal restructuring to strengthen its long-term...
Amazon Eyes Smartphone Comeback — 'Transformer' Project Repo

Amazon Eyes Smartphone Comeback — 'Transformer' Project Reportedly Targets AI-Driven Future

Amazon.com Inc (NASDAQ:AMZN) is dialing up a second attempt at the smartphone market. More than a decade after the Fire Phone was scrapped, the...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity P

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity P

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients

NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April...
« Prev 1 69 70 71 72 73 79 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms